Similarly, tuberculosis patients show increased CD226+ NK and T cell subsets with enhanced production of CD107a and IFN-γ, suggesting CD226 as a biomarker for clinical outcomes and disease progression in tuberculosis [71]. This evidence concerns the gene CD226 and tuberculosis.